TFOS DEWS II is an epic global consensus on dry eye disease. Join us as we go through each section with the scientists behind the work. Find out more here: Dry eye was first defined as a disease—not just a syndrome—in 1995. In part 1 of this 2-part episode, Drs. Craig and Nichols explain that evidence had evolved showing that tear film quality was as important as quantity, leading TFOS to arrive at an updated definition in 2007. Research into the clinical and basic science components of the disease continued to accelerate, and emerging understanding indicated the need for an updated definition. The group was very cognizant of the importance of creating a definition that was global and would work for clinicians worldwide.
Jennifer Craig, PhD, MSc, BSc (Hons), FCOptom, FAAO, FBLCA, FACLS is Associate Professor at the University of Auckland, New Zealand, and Vice-Chair of TFOS DEWS II.
Kelly K. Nichols, OD, MPH, PhD, FAAO, is Dean of the School of Optometry at the University of Alabama at Birmingham and has served extensively on the TFOS Executive Board and Steering Committees.
ABOUT OUR SPONSORS
SIGHT SCIENCES
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world’s most prevalent eye diseases. The company’s surgical glaucoma product portfolio features the OMNI® Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s product portfolio also includes
TearCare® for ophthalmologists and optometrists. TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. TearCare’s innovative, “equipment-light” product design and the intuitive procedure it facilitates create a highly attractive clinical and economic model for eye care providers.
LACRIMEDICS INC.
Lacrimedics, Inc. was founded in 1984 by Ophthalmologist, Robert S. Herrick, M.D., a specialist in corneal and external diseases since the 1970s. Dr. Herrick has developed many innovative products and procedures used in the care of patients with Dry Eye Disease (DED) and Lacrimal System Dysfunction (LSD). The company's proprietary products include the Dissolvable VisiPlug Lacrimal Plug for medium-term Occlusion Therapy lasting approximately 180 days and the following products for long-term occlusion therapy: Herrick Lacrimal Plug for intracanalicular comfort with no pop out , the ComfortTip Punctal Occluder featuring a collapsible tip for ease of insertion, increased patient comfort, and ease of insertion, and the AccuFlo Punctal Occluder for when the patient experiences epiphora or when less occlusion is needed. Lacrimedics also pioneered the development of the Collagen Plugs for the Lacrimal Efficiency Test in the early 1980s. This revolutionary product provides a simple and cost-effective method to diagnose Dry Eye Disease and determine if the patient will respond favorably to Occlusion Therapy.
#TFOS #TFOSDEWSII #DryEyeDisease #Drs.JenniferCraig #KellyNichols #OcularSurfaceAcademy
0 Comments